AB1417 HOW TO DIAGNOSE: JUVENILE PSORIATIC ARTHRITIS. MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY IN CHILDREN WITH SUSPECTED DIAGNOSIS
Authors: N. Palmou-Fontana, I. Calvo, G. Diaz Cordoves Rego, A. Garcia-Rogero, J. C. Lopez Robledillo, B. P. Magallares López, P. Mesa del Castillo, E. Moreno Ruzafa, C. Redondo-Figuero, M. Steiner, P. Collado
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Juvenile psoriatic artritis (JPSA), a subtype of juvenile idiopathic arthritis (JIA), constitutes 5% of JIA. The literature is inconsistent regarding features of JPSA, and physicians debate whether it is a distinct entity within JA. Moreover, the criteria diagnosis for JPsA is currently in debate.There are two pediatric diagnostic classifications based on clinical criteria: ILAR classification criteria and Vancouver classification criteria. Classification of JIA has been a great debate since this entity disappeared. [1] The CASPAR criteria are standard in adults. These criteria have a specificity of 91.4% and a sensitivity of 98.7%, makingdiagnostic classification easier. However, the peculiarities of childhood cause some differences to consider. <h3>Objectives</h3> To compare 3 diagnostic criteria for JPSA ILAR, Vancouver and CASPAR. <h3>Methods</h3> Multicenter, cross-sectional study of data from children with JPsA (diagnosis by prescritor physician) who consecutivelly attended in ped-rheumatology outpatient clinic and enrolled from 9 centers within the last 1.5 years. Sociodemographic, clinical characteristics and family history of Psoriasis were collected to assess compliance with diagnostic classification criteria using using the Cohen's Kappa statistic index. <h3>Results</h3> Forty eight children were included with the following sociodemographics characteristics;(table1) Thirty eight children who met the VANCOUVER criteria (80,9%) while thirty two children met the ILAR criteria (68.1%). As for the CASPAR criteria, thirty eight children were diagnosed (80.9%). The diagnostic agreement between the ILAR and CASPAR criteria and ILAR and Vancouver criteria (diagnosed defined) was weak (K=0.67 and K=0.67). In contrast, the agreement was total (K=1 between the CASPAR and Vancouver criteria. <h3>Conclusion</h3> Despite minimal changes between the Vancouver and ILAR criteria, the ILAR exclusion criteria limit the diagnosis of PsA in childhood. Given that the CASPAR and Vancouver were able to detect a significant number of patients with PsA in our series (predominantly adolescents), the application of the CASPAR criteria in the subgroup of children with late onset could be considered. <h3>References</h3> [1] Alberto martini, Angelo Ravelli, Tad Avcin, et al. Toward new Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus; J Rheumatol. 2019: 46(2):190-197. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Natalia Palmou-Fontana: None declared, Inmaculada Calvo Speakers bureau: ABVIEE, NOVARTIS, JANSEN, GSK, GISELLA DIAZ CORDOVES REGO: None declared, ADRIAN GARCIA-ROGERO: None declared, Juan Carlos Lopez Robledillo: None declared, Berta Paula Magallares López: None declared, Pablo Mesa del Castillo: None declared, ESTEFANIA MORENO RUZAFA: None declared, CARLOS REDONDO-FIGUERO: None declared, MARTINA STEINER: None declared, PAZ COLLADO: None declared.